#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12234	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2102	578.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1685	1685	T	680	T,C	632,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12234	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2102	578.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1419	1419	C	745	C	702	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3561	643.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1625	1625	A	777	A	741	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3561	643.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2259	2259	C	757	C,A	713,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3561	643.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2333	2333	A	752	A	713	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3561	643.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2885	2885	C	721	C	674	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1804	folP	855	855	100.0	folP.l15.c4.ctg.1	1534	117.0	1	SNP	p	R229S	1	.	.	685	687	AGC	960	962	AGC	186;183;182	A;G;C	172;171;168	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5194	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3535	146.5	1	SNP	p	S91F	1	.	.	271	273	TTC	657	659	TTC	161;162;160	T;T;C	155;155;155	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5194	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3535	146.5	1	SNP	p	D95G	1	.	.	283	285	GGC	669	671	GGC	154;152;153	G;G;C	149;147;147	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5194	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3535	146.5	1	SNP	p	G95N	0	.	.	283	285	GGC	669	671	GGC	154;152;153	G;G;C	149;147;147	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1548	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1304	118.1	1	SNP	p	G45D	0	.	.	133	135	GGC	548	550	GGC	183;186;186	G;G;C	173;174;175	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	836	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1120	74.6	0	.	n	.	0	A197.	DEL	197	197	A	626	626	A	200	A	188	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	0	.	p	.	0	P367L	NONSYN	1099	1101	CCC	1340	1342	CTC	179;178;180	C;T,C;C	169;96,72;168	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1391	1393	GTC	173;173;170	G;T;C	159;160;156	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	1	SNP	p	D86N	0	.	.	256	258	GAC	497	499	GAC	195;198;197	G;A;C	178;179;181	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	1	SNP	p	R87W	0	.	.	259	261	CGT	500	502	CGT	196;198;199	C;G;T,A	182;184;181,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	1	SNP	p	S87R	1	.	.	259	261	CGT	500	502	CGT	196;198;199	C;G;T,A	182;184;181,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	1	SNP	p	R87I	0	.	.	259	261	CGT	500	502	CGT	196;198;199	C;G;T,A	182;184;181,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	667	4582	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2878	158.4	1	SNP	p	S88P	0	.	.	262	264	TCC	503	505	TCC	202;200;197	T;C;C	184;183;184	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4044	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2659	151.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1353	1355	TGC	190;192;194	T,C;G;C	175,1;178;181	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4044	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2659	151.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1563	1565	GGC	209;205;203	G,T;G;C	197,1;191;187	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1279	1281	GCA	196;196;196	G;C;A	185;186;188	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1282	1284	ATC	197;196;196	A;T;C	187;184;186	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1294	1296	GTG	204;203;202	G;T;G	191;189;189	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1294	1296	GTG	204;203;202	G;T;G	191;189;189	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1798	1800	ACC	165;165;165	A;C;C	153;154;155	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1852	1854	GCG	158;157;156	G;C,T;G	144;130,1;135	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1852	1854	GCG	158;157;156	G;C,T;G	144;130,1;135	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1975	1977	GGC	151;152;153	G;G;C	144;145;148	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1984	1986	GGC	157;157;162	G;G;C	148;146;153	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3454	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2432	141.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2002	2004	TCG	153;152;148	T,G;C;GCCC,GCCCC	104,5;122;129,2	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4974	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3190	155.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1699	1701	CCG	157;153;153	C;C;G	142;143;140	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2054	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1772	115.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	547	547	C	133	C	126	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	316	318	GAA	204;202;199	G;A;A	191;189;184	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	604	606	GAT	194;197;198	G;A;T	183;184;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	727	729	TCA	224;227;227	T;C;A	203;207;210	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	856	858	GTC	191;194;195	G;T;C	181;183;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	R258H	NONSYN	772	774	CGT	976	978	CAT	184;184;184	C;A;T	177;178;178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1186	1188	GCA	167;169;169	G;C;A	158;160;160	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	1	SNP	p	G120K	1	.	.	358	360	AAG	562	564	AAG	197;195;199	A;A;G	189;189;190	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	1	SNP	p	A121D	1	.	.	361	363	GAC	565	567	GAC	197;197;196	G;A;C	190;190;188	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2382	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1394	167.5	1	SNP	p	D121N	0	.	.	361	363	GAC	565	567	GAC	197;197;196	G;A;C	190;190;188	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8564	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4863	175.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1944	1946	AAT	183;180;181	A;A;T	172;170;171	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1060	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1073	98.1	1	SNP	p	V57M	1	.	.	169	171	ATG	560	562	ATG	211;212;214	A;T,G;G	200;199,2;201	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
